Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication

  • 182 Accesses

Correction to: Oncogenesis

https://doi.org/10.1038/oncsis.2017.76 Published online 11 September 2017

The FAB classification of OCI-M2, GF-D8, CMK-11-5, and THP-1 cell lines in Table 1 was wrong. This error has been fixed in the revised table.

Table 1 Synergy score of T-3775440/pevonedistat combination in an AML cell panel

Author information

Correspondence to K. Nakamura.

Additional information

The original article can be found online at https://doi.org/10.1038/oncsis.2017.76.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ishikawa, Y., Nakayama, K., Morimoto, M. et al. Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication. Oncogenesis 8, 51 (2019) doi:10.1038/s41389-019-0160-0

Download citation